INVIRAGEN
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine to protect against dengue fever, a disease that threatens 2.5 billion people across the globe. Inviragen is also developing a vaccine to protect against West Nile for the North American market, a nasal combination vaccine to protect against both plague and smallpox for biodefense, and a unique vaccine to protect against avian influenza for global markets.
INVIRAGEN
Industry:
Biotechnology Health Care Medical
Founded:
2003-01-01
Address:
Fort Collins, Colorado, United States
Country:
United States
Website Url:
http://www.inviragen.com
Total Employee:
11+
Status:
Active
Contact:
9703720693
Email Addresses:
[email protected]
Total Funding:
15 M USD
Technology used in webpage:
IPv6 Google Apps For Business Cloudflare Hosting Cloudflare DNS
Similar Organizations
Henry Ford Health System
Henry Ford Health System (HFHS) is one of the nationโs leading comprehensive, integrated health systems.
Current Advisors List
Investors List
Charter Life Sciences
Charter Life Sciences investment in Series A - Inviragen
EDBI
EDBI investment in Series A - Inviragen
Phillip Private Equity
Phillip Private Equity investment in Series A - Inviragen
Venture Investors
Venture Investors investment in Series A - Inviragen
Official Site Inspections
http://www.inviragen.com
- Host name: 104.21.16.169
- IP address: 104.21.16.169
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Inviragen"
Inviragen - Crunchbase Company Profile & Funding
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine โฆSee details»
Takeda Pharmaceuticals North America, Inc.
May 7, 2013 Inviragen has created innovative products using its expertise in viral vaccines. The companyโs lead candidate, DENVax, is a four-strain recombinant viral vaccine for the โฆSee details»
Inviragen 2025 Company Profile: Valuation, Investors, Acquisition ...
Inviragen General Information Description. Developer of vaccines to protect against various infectious diseases. The company offers its products to protect against dengue viruses, as well โฆSee details»
Inviragen, Inc. - LinkedIn
Inviragen, Inc. | 192 followers on LinkedIn. Vaccine R&D. Tory Burch Foundation Non-profit Organizations New York, New YorkSee details»
Takeda to Acquire Inviragen, Inc. - PR Newswire
May 7, 2013 OSAKA, Japan and DEERFIELD, Ill. and FORT COLLINS, Colo., May 7, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Inviragen, Inc. โฆSee details»
Organization | Inviragen
Inviragen Report issue. For profit Phase 1 Phase 2. Founded: Fort Collins CO United States ... Organization Overview. First Clinical Trial. 2010 NCT01224639. First Marketed Drug. None โฆSee details»
Inviragen - Products, Competitors, Financials, Employees, โฆ
About Inviragen. Inviragen develops life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's product candidates included a vaccine to protect against โฆSee details»
Inviragen, Inc. Overview | SignalHire Company Profile
Inviragen, Inc. is a private company that has been in the industry for 19 years. The company currently specializes in the Pharmaceuticals area. ... Organization Website. inviragen.com . โฆSee details»
Inviragen Inc - Company Profile and News - Bloomberg Markets
Inviragen, Inc. develops life-saving vaccines to protect against various infectious diseases. The Company offers products to protect against dengue viruses, as well as swine-origin, โฆSee details»
Inviragen, Inc.:Company Profile & Technical Research,Competitor โฆ
Inviragen, Inc. is headquartered in United States Colorado. Inviragen, Inc. was founded in 2003. Inviragen, Inc. has a total of 35 patents . Related Topics. Toxoid DNA vaccination Smallpox โฆSee details»
Inviragen - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 6, 2009: Series A - โฆSee details»
Takeda to acquire Inviragen for $35m - pharmaphorum
May 8, 2013 Inviragen's lead candidate, DENVax, is a four-strain recombinant viral vaccine for the prevention of dengue infection, which is currently being evaluated in phase 2 clinical trials.See details»
Inviragen โ Venture Investors
Sep 7, 2016 Together with Charter Life Sciences, Venture Investors pledged the support that enabled Inviragen to reach a merger agreement with Singapore based SingVax. This support โฆSee details»
Inviragen, Inc. (Inviragen, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅ โฆ
These vaccines are supplied annually for use in the Expanded Program on Immunization and for domestic needs. For more information, please visit About Inviragen, Inc. Inviragen is focused โฆSee details»
Inviragen - Contacts, Employees, Board Members, Advisors & Alumni
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases. New. Resources. ... Experience the new Crunchbase, powered by AI . Organization. โฆSee details»
Inviragen Merges with SingVax and Completes $15 million Series A ...
Oct 6, 2009 Inviragen's lead vaccine is designed to protect against dengue fever, a mosquito-borne disease that threatens 3.6 billion people who live in tropical and subtropical regions โฆSee details»
Takeda buys vaccines specialist Inviragen - PMLiVE
May 8, 2013 Takeda has gained the rights to vaccines candidates against emerging infectious diseases, including dengue and hand, foot and mouth disease, as part of a $250m deal to โฆSee details»
Inviragen Company Profile - Life Science Intelligence
Inviragen. Safe and effective vaccines for the treatment of infectious diseases, especially in emerging economies. Subscribe Now Request Info Get a Demo and See the Full Profile Get a โฆSee details»
Inviragen - Company Information, Competitors, News & FAQs
Find useful insights on Inviragen's company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at Inviragen.See details»
Novartis receives FDA accelerated approval for Vanrafia® โฆ
Apr 3, 2025 Ad hoc announcement pursuant to Art. 53 LR. Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS โฆSee details»